<VariationArchive RecordType="classified" VariationID="1703193" VariationName="NC_000019.9:g.(?_11222190)_(11227674_?)del" VariationType="Deletion" Accession="VCV001703193" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-08-06" DateCreated="2022-09-03" MostRecentSubmission="2022-09-03">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1695584" VariationID="1703193">
      <GeneList>
        <Gene Symbol="LDLR" FullName="low density lipoprotein receptor" GeneID="3949" HGNC_ID="HGNC:6547" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089463" stop="11133820" display_start="11089463" display_stop="11133820" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11200037" stop="11244505" display_start="11200037" display_stop="11244505" Strand="+" />
          </Location>
          <OMIM>606945</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000019.9:g.(?_11222190)_(11227674_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="11222190" innerStop="11227674" display_start="11222190" display_stop="11227674" variantLength="5485" />
      </Location>
      <OtherNameList>
        <Name>NM_000527.4(LDLR):c.1061-?_1845+?del</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_11222190)_(11227674_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_11222190)_(11227674_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.9:g.(?_11222190)_(11227674_?)del AND Hypercholesterolemia, familial, 1" Accession="RCV002280316" Version="1">
        <ClassifiedConditionList TraitSetID="7435">
          <ClassifiedCondition DB="MedGen" ID="C0745103">Hypercholesterolemia, familial, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2021-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-09-03" MostRecentSubmission="2022-09-03">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/4ec3a403-6eee-4822-846f-2a5dbf6e9d6d</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="7435" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15983" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, MODIFIER OF</ElementValue>
                <XRef Type="Allelic variant" ID="600946.0028" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LDL RECEPTOR DISORDER</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPER-LOW-DENSITY-LIPOPROTEINEMIA</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
                <XRef Type="MIM" ID="144400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fredrickson type IIa hyperlipoproteinemia</ElementValue>
                <XRef ID="397915002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-beta-lipoproteinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, familial, 1</ElementValue>
                <XRef ID="MONDO:0007750" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHC</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FH</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/CG71</URL>
                <CitationText>National Institute for Health and Clinical Excellence, Identification and management of familial hypercholesterolaemia, 2008 [Updated: 4 October 2019]</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2012">
                <ID Source="PubMed">22364837</ID>
              </Citation>
              <Citation Type="general" Abbrev="IPMFH, 2004">
                <ID Source="PubMed">15177124</ID>
              </Citation>
              <Citation Type="general" Abbrev="NLAEP, 2011">
                <ID Source="PubMed">21600525</ID>
              </Citation>
              <Citation Type="general" Abbrev="Int'l FH Foundation, 2014">
                <ID Source="PubMed">24418289</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="Feldman et al., 2015">
                <ID Source="PubMed">25404096</ID>
              </Citation>
              <Citation Type="general" Abbrev="EAS, 2014">
                <ID Source="PubMed">25053660</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2014">
                <ID Source="PubMed">24636176</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2013">
                <ID Source="PubMed">23725921</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="391665" DB="Orphanet" />
              <XRef ID="C0745103" DB="MedGen" />
              <XRef ID="MONDO:0007750" DB="MONDO" />
              <XRef Type="MIM" ID="143890" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="5022323" SubmissionDate="2022-08-27" DateLastUpdated="2022-09-03" DateCreated="2022-09-03">
        <ClinVarSubmissionID localKey="4ec3a403-6eee-4822-846f-2a5dbf6e9d6d" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002568347" DateUpdated="2022-09-03" DateCreated="2022-09-03" Type="SCV" Version="1" SubmitterName="ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel" OrgID="508055" OrganizationCategory="consortium" OrgAbbreviation="ClinGen FH VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-01">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/4ec3a403-6eee-4822-846f-2a5dbf6e9d6d</URL>
          </Citation>
          <Comment>The NM_000527.4(LDLR):c.1061-?_1845+?del variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PVS1, PP1_Moderate, PM2 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1101/2021.03.17.21252755). The supporting evidence is as follows: PVS1 - Deletion of exons 8 through 12, predicted to lead to out-of frame consequence, so PVS1 is Met. PP1_moderate - variant segregates with FH phenotype in 5 informative meiosis in 1 family from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge. PM2 - No population data was found for this variant in gnomAD (gnomAD SVs v2.1). PP4 - Variant meets PM2. Variant identified in 1 index case who fulfils SB criteria for FH from Cardiovascular Research Group,Instituto Nacional de Saude Doutor Ricardo Jorge.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Semidominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen FH ACMG Specifications v1-2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/mg2eil60/clingen_fh_acmg_specifications_v1-2.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000527.4(LDLR):c.1061-?_1845+?del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_11222190)_(11227674_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007750" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11977945</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5022323" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007750" MappingRef="MONDO">
        <MedGen CUI="C0745103" Name="Hypercholesterolemia, familial, 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

